Genzyme's Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design
News Apr 20, 2012
Genzyme, a Sanofi company , today announced that its Biologics Support Center in Framingham, Mass., received a Gold certification under the U.S. Green Building Council's LEED(R) (Leadership in Energy and Environmental Design) Green Building Rating System(TM). This is the tenth Genzyme building to achieve a LEED rating for sustainable construction and design.
The Framingham Biologics Support Center is an administrative and lab building connected to Genzyme's newly approved manufacturing facility that produces Fabrazyme(R) (agalsidase beta). The 186,000 square foot facility accommodates approximately 550 employees, including manufacturing, support, and administrative staff for the manufacturing plant.
"The achievement of ten LEED certifications demonstrates Genzyme's ongoing dedication to pursuing and meeting high standards in every aspect of our business," said Genzyme's President and CEO David Meeker. "We are committed to being a responsible corporate citizen and a good neighbor in our communities."
Biologics Support Center Features
LEED certification provides independent, third-party verification that a building was designed and built using strategies aimed at achieving high performance in five key areas of human and environmental health: energy efficiency, water savings, materials selection, sustainable site development, and indoor environmental quality. The Framingham Biologics Support Center was designed to achieve goals in each of these areas.
Multidisciplinary Study Suggests New Strategy for Drug DiscoveryNews
A joint industry/academia study of a cancer target protein reveals unusual relation between binding site flexibility and drug-target lifetime. The results, , suggest a new strategy for drug discovery.READ MORE
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE